Start with a clear decision framework
Begin by defining the outcomes you need: specific tumor models, PK/PD depth, GLP or non-GLP status, and expected timelines. When you’re vetting a partner for complex oncology work, look beyond marketing and evaluate a preclinical oncology CRO by how well their capabilities map to each outcome. Keep this framework handy as you compare proposals so technical fit drives your choice, not persuasive sales language.
Technical capabilities that must be checked
Confirm assay validity, historical control data, and reproducibility for your tumor types. Ask for specifics: cell-line provenance, authentication steps, mycoplasma testing frequency, and validated endpoint assays. Verify pharmacokinetic sampling methods and bioanalysis platforms. If the CRO cannot supply clear SOP references or validation reports on request, mark them lower on your shortlist.
Study design and translational relevance
Insist on a pre-study review that ties dosing, schedule, and endpoints to human biology. Look for CROs that propose adaptive elements when justified by pilot data. Confirm they can run the right combination of in vivo and ex vivo readouts so you’ll have translational signals rather than isolated measurements. Poorly designed controls and unrealistic dosing are the most common reasons programs stall.
Data integrity, QA, and reporting
Ask for raw data access, audit trails, and sample chain-of-custody procedures. Request examples of final reports with raw data excerpts included. Check whether their quality assurance team performs blinded reviews and how they handle outliers. Reports should let your team reproduce analysis decisions without extra clarification calls.
Regulatory compliance and safety practices
Verify animal welfare program details and regulatory documentation practices for your target markets. Confirm their experience submitting data packages to regulatory bodies relevant to your program. If you expect GLP data, require clear GLP scope and past GLP inspection outcomes. A gap here can force costly repeat studies later.
Communication, project management, and oversight
Prefer CROs that assign a single accountable project lead and deliver a milestone-based timeline with weekly touchpoints. Ask how they escalate technical issues and where decisions require sponsor sign-off. Frequent, clear updates reduce rework and preserve timelines.
Costs, timelines, and contract clarity
Compare fixed-price line items for critical milestones and add-ons for contingency work. Insist on delivery deadlines tied to milestones, not vague ranges. Ensure IP ownership, data access rights, and publication clauses are explicit in the contract. Vague terms here create disputes that slow programs down.
Common pitfalls to avoid
Don’t accept vague assay descriptions, broad disclaimers about intellectual property, or promises of “fast” timelines without documented capacity. Avoid vendors that cannot provide recent references for similar studies. Be cautious when a low bid lacks detailed resource plans; that cost saving often hides schedule risk.
Experience and a real-world anchor
We rely on teams with hands-on study execution and on documented sources. Our approach aligns with practices recommended by the U.S. National Cancer Institute (NCI) for preclinical oncology study design, and we’ve collaborated with groups that provide oncology pharmacology services to ensure robust PK/PD translation. Ask to see study examples and references that match your indication and model complexity before you commit.
Final synthesis
A practical framework focuses decisions on measurable technical fit, transparent data practices, and contractual clarity. Apply each checklist item consistently across bidders; that disciplined approach surfaces the partner most likely to deliver usable, regulator-ready data. When those criteria align, you’ll find a partner whose processes and reports reduce risk and speed decisions—qualities we value and that are reflected in collaborators like KCI Biotech.